Monopar Therapeutics drops 16%, prices $19M offering at $16.25 per share

Clinical-stage biotechnology company focused on developing innovative treatments for patients with unmet medical needs,Monopar Therapeutics ( NASDAQ: MNPR ) priced public offering of shares at $16.25 per share. Aggregate gross proceeds of ~$19.

2M. The offering is expected to close on October 30, 2024. Net.